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Dear Sir,
Recently Bang, et al.1 reported a case of a 29 year-old obese woman who was hos-
pitalized with pulmonary arterial hypertension (PAH) and a history of having tak-
en phentermine hydrochloride 37.5 milligrams daily for 35 days. Since common 
etiologies of PAH were excluded by the patient’s history, examination procedures, 
and hospital course, the authors suggest this is the first case of phentermine-in-
duced PAH. We suggest instead this is a case of idiopathic pulmonary arterial hy-
pertension (IPAH) rather than PAH secondary to therapeutic phentermine. 
The authors suggest, based on one case report, that phentermine mono-therapy 
produces the same increase in incidence of PAH previously seen in patients treated 
with fenfluramine mono-therapy and in patients treated with a combination of fen-
fluramine and phentermine. However, a survey of 95 European cases of PAH by 
Abenhaim, et al.2 found that of the 30 patients that had a history of taking anorexic 
agents, 24 had taken a fenfluramine, but none had taken phentermine. Moreover, 
Rich, et al.,3 in a North American prospective study in which 579 patients with 
pulmonary hypertension were studied, found that the odds ratios for an association 
of pulmonary hypertension and fenfluramine to be 7.5, an odds ratio for a similar 
association for phentermine of 0.6, and concluded that fenfluramines, but not 
phentermine are risk factors for PAH. Since fenfluramines were taken off-market 
in 1997 there have been no subsequent reports linking PAH or IPAH to anorectic 
medicines. Hence the literature does not support the contention of Bang, et al. that 
phentermine mono-therapy has caused an increased incidence of secondary PAH 
similar to that caused by fenfluramine.
Physicians in other countries may not be aware that phentermine has long been 
the most widely used anti-obesity medicine in the United States. A recent survey 
of United States obesity treatment specialists found that for 97%, phentermine was 
their first choice among the available anti-obesity drugs.4 The majority of physi-
cians surveyed reported they prescribed phentermine long-term in any patient pro-
vided the medicine was effective and produced no intolerable side effects. The 
longest duration of phentermine therapy reported in the literature has been forty 
years with no serious adverse effects.5 The survey confirmed that most specialists 
have employed doses higher than the maximum dose of 37.5 milligrams daily rec-
ommended by the U.S. Food and Drug Administration (FDA)-approved label. 
There are other reports of the safe use of higher doses.4,6-9 Thus, in spite of contin-
ued widespread use of phentermine for longer durations and higher doses than rec-Ed J. Hendricks and Richard B. Rothman
Yonsei Med J   http://www.eymj.org   Volume 52   Number 5   September 2011 870
long-term, dose ranging, clinical trials with phentermine; 
we concur that such trials are needed and should be con-
ducted. Meanwhile, while we await trials, phentermine treat-
ment should not be withheld from the obese because of fear 
of theoretical but unproven adverse effects.  
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ommended by the FDA-approved label, there is no report 
of an increased incidence of pulmonary hypertension due to 
phentermine in the U.S. The incidence of IPAH is approxi-
mately one case per million per year in the general popula-
tion. Since phentermine is so widely used, it is reasonable 
to expect an occasional patient diagnosed with IPAH will 
coincidently have taken phentermine.
PAH and IPAH are characterized by an increase in pul-
monary vascular resistance due to progressive obliteration 
of pulmonary arterioles, which in turn are induced by pul-
monary arteriole smooth muscle cell proliferation and arte-
riolar vasoconstriction with accompanying inflammation 
and thrombosis. One hypothesis to explain fenfluramine-in-
duced PAH is that fenfluramine releases 5-hydroxytrypto-
phan (5-HT) via the 5-HT transporter (SERT), and that the 
increased concentration of plasma 5-HT provokes pulmo-
nary vasoconstriction and pulmonary arterial smooth muscle 
cell proliferation.10 However, recent data raises questions 
about this hypothesis.11 5-HT is also thought to play a cen-
tral role in the pathogenesis of IPAH. Bang, et al. imply that 
phentermine is active as a serotonin transporter producing 
increases in 5-HT levels, and therefore has the potential to 
cause PAH. However, Rothman, et al.12 have shown previ-
ously that phentermine has considerably less potent SERT 
substrate activity, and is considerably less effective in elevat-
ing plasma 5-HT compared to fenfluramine, and compared 
to the commonly abused stimulants methamphetamine and 
3,4-methylenedioxymethamphetamine. In another study 
Rothman, et al. found that phentermine produced minimal 
increases in 5HT, insufficient to provoke pulmonary arteri-
olar smooth muscle proliferation.13 These studies suggest 
that it is unlikely phentermine could induce PAH by the 
mechanism proposed by Bang, et al.    
In summary we suggest that phentermine, after 52 years 
of widespread use has proven to be both effective and safe. 
Historically, an association between phentermine mono-
therapy and PAH has been suggested but confirming evi-
dence has not appeared. Currently, while we have few ef-
fective pharmacologic agents to include in obesity treatment, 
patients and physicians are fortunate to have phentermine 
available. Bang, et al. are correct in noting the absence of 